La Combinación Doble: Aceptación y Polémica

Extracto de bibliografía

1. Bangsberg, D.R. and others. Adherence to HAART predicts progression to AIDS. 8^th Conference on Retroviruses and Opportunistic Infections. Chicago. February 4-8, 2001. Poster 483.Bernstein, B. and others. Absence of resistance to Kaletra (ABT-378/r) observed through 48 weeks of therapy in antiretroviral-naive subjects. 8^th CROI. Poster 453.

2. Brun, S. and others. Patterns of protease inhibitor cross-resistance in viral isolates with reduced susceptibility to ABT-378. 8^th CROI. Poster 452.

3. Burger, D. and others. Both short-term virological efficacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics (PK) in HIV-1-infected Thai patients. 8^th CROI. Poster 730.
   Advertisement

4. Burger, D. and others. Indinavir pharmacokinetics are related to efficacy and toxicity. 7^th European Conference on Clinical Aspects and Treatment of HIV-Infection. Lisbon. October 23-27, 1999. Poster 826.

5. Cadman, J. The great salvage therapy drug juggle. GMHC Treatment Issues 12(4): 1-6. April 1998.

6. Cameron, D.W. and others. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13(2): 213-224. February 4, 1999.

7. Cameron, D.W. and others. Three-year follow-up and conditional outcomes survival analysis of ritonavir (RTV) plus saquinavir (SQV) therapy in HIV infection. 7^th CROI. San Francisco. January 30-February 2, 2000. Poster 533.

8. Chaillou, S. and others. Does ritonavir "baby" dose induce specific mutations in salvage combination therapy? A VIRADAPT sub-study. 40^th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto. September 17-20, 2000. Poster 1267.Condra, J.H. and others. Resistance to HIV-1 protease inhibitors and predicted responses to therapy. 3^rd International Workshop on Salvage Therapy for HIV Infection. Chicago. April 12-14, 2000. Oral presentation 2.

9. Danner, S. Breaking new ground: the future of HIV therapy; redefining the art of HIV management. 5^th International Congress on Drug Therapy in HIV Infection (satellite symposium). Glasgow, Scotland. October 23, 2000. Lecture 6.

10. Degen, O. and others. Amprenavir (APV) and ritonavir (RTV): intraindividual comparison of different doses and influence of concomitant NNRTI on steady-state pharmacokinetics in HIV-infected patients. 8^th CROI. Poster 739.